What is the JUXTAPID Risk Evaluation and Mitigation Strategy (REMS) Program?

Due to the risk of hepatotoxicity, JUXTAPID is only available through a restricted distribution program required by the US Food and Drug Administration called the JUXTAPID REMS Program.

The goal of the JUXTAPID REMS program is to mitigate the risk of hepatotoxicity associated with the use of JUXTAPID by ensuring that

1. Prescribers are educated about the approved indication for JUXTAPID, the risk of hepatotoxicity associated with the use of JUXTAPID, and the need to monitor patients during treatment with JUXTAPID as per product labeling
2. JUXTAPID is dispensed only to patients with a clinical or laboratory diagnosis consistent with HoFH
3. Patients are informed about the risk of hepatotoxicity associated with the use of JUXTAPID and the need for baseline and periodic monitoring

JUXTAPID REMS Program Requirements

- Certification of prescribers of JUXTAPID
- Patient counseling
- Certification of pharmacies to dispense JUXTAPID
- A valid JUXTAPID REMS Program Prescription Authorization Form signed by a certified prescriber, and
- A completed JUXTAPID REMS Program Patient-Prescriber Acknowledgement Form signed by the patient and a certified prescriber must be on file

Because of the risk of hepatotoxicity with the use of JUXTAPID, prescribers are recommended to monitor liver function as described in the Prescribing Information.

Please see accompanying full Prescribing Information for JUXTAPID, including BOXED WARNING for hepatotoxicity.
Prescriber Requirements

Only certified healthcare providers can prescribe JUXTAPID. To become certified, prescribers must:

1. **Review** the Prescribing Information, and this Fact Sheet

2. **Complete** the online JUXTAPID REMS Program Prescriber Training Module and the Prescriber Enrollment Form. Send the Prescriber Enrollment Form to the JUXTAPID REMS Coordinating Center by fax: 1-855-898-2498 or email: REMS@aegerion.com

3. **Agree**
   - To counsel each patient on the JUXTAPID REMS Program including the indication for use, the risk of hepatotoxicity and the need for monitoring using the Patient Guide
   - To complete a JUXTAPID REMS Program Patient-Prescriber Acknowledgement Form with each patient

Prescribers must also fax a JUXTAPID REMS Program Prescription Authorization Form for each prescription to the JUXTAPID REMS Program.

Pharmacy Requirements

Only certified pharmacies can purchase, dispense, and distribute JUXTAPID. To become certified, pharmacies must select a representative who will complete the certification process:

1. **Review** the Prescribing Information, and this Fact Sheet

2. **Complete** the online JUXTAPID REMS Program Pharmacy Training Module and the Pharmacy Enrollment Form and send it with the Certificate of Completion for the Pharmacy Training Module to the JUXTAPID REMS Coordinating Center by fax: 1-855-898-2498 or email: REMS@aegerion.com

3. **Agree** to train all relevant pharmacy staff, to implement processes and procedures to ensure prescriber certification, to be audited if necessary, and to provide prescription data

Visit [www.juxtapidREMSprogram.com](http://www.juxtapidREMSprogram.com) to access training materials and begin certification.